Every Form 4 that Lisata Therapeutics Inc (LSTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LSTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSTA filings page.
Lisata Therapeutics President & CEO David J. Mazzo reported new equity awards and related tax withholdings. On January 9, 2026, he received 81,000 shares of restricted stock under the company’s 2018 Equity Incentive Compensation Plan at a stated price of $0. These restricted shares vest in four equal installments, starting on the grant date and then on each of the first three anniversaries.
On the same date, he was granted a stock option for 40,000 shares of common stock with an exercise price of $1.97 per share, also vesting in four equal annual installments beginning on the grant date. To cover tax liabilities from vesting restricted stock, a total of 41,096 shares of common stock were withheld at $1.97 per share. After these transactions, Mazzo directly beneficially owned 311,890 shares of common stock, including 124,750 unvested restricted shares.
Lisata Therapeutics, Inc. reported equity awards and related tax withholdings for senior executive James Nisco, SVP Finance, Treasurer and Chief Accounting Officer. On January 9, 2026, he received 15,000 shares of restricted common stock at a price of $0 under the company’s 2018 Equity Incentive Compensation Plan. These restricted shares vest in four equal parts, with one quarter vesting on the grant date and additional quarters vesting on each of the first, second and third anniversaries of the grant.
The filing also shows tax-related share withholdings: blocks of 2,131, 2,131, 1,137 and 781 common shares were withheld at $1.97 per share to cover taxes upon vesting of restricted stock. After these transactions, Nisco directly held 32,311 shares of common stock, which include 20,750 unvested restricted shares.
In addition, Nisco was granted a stock option for 7,000 shares of common stock at an exercise price of $1.97 per share. One quarter of the option vested on the grant date, with further quarters scheduled to vest on the first, second and third anniversaries of January 9, 2026, and the option expires on January 9, 2036.
Lisata Therapeutics, Inc. executive Tariq Imam, SVP Business Development and General Counsel, reported new equity awards and related tax withholdings. On January 9, 2026, he received 15,000 shares of common stock as restricted stock awards under the company’s 2018 Equity Incentive Compensation Plan at a price of $0. These restricted shares vest in four equal parts: one-quarter on the grant date and one-quarter on each of the first three anniversaries.
After this grant, he directly owned 39,579 shares of common stock, including 17,750 unvested restricted shares. Several transactions coded "F" show a total of 1,401, 840, 747 and 513 shares of common stock withheld at $1.97 per share to cover tax liabilities from restricted stock vesting, leaving 36,078 common shares directly owned. Imam was also granted a stock option for 7,000 shares at an exercise price of $1.97 per share, with one-quarter vesting immediately on January 9, 2026 and the remainder vesting in three annual installments through an expiration date of January 9, 2036.
Lisata Therapeutics executive Kristen K. Buck, EVP, R&D and CMO, reported new equity awards and related tax-withholding transactions. On 01/09/2026 she received 25,000 shares of common stock as restricted stock awards under Lisata’s 2018 Equity Incentive Compensation Plan, vesting in four equal annual installments starting on the grant date. On the same date she was also granted stock options for 13,000 shares at an exercise price of $1.97 per share, with one-fourth vesting immediately and the rest in equal annual installments through 01/09/2036.
To cover tax liabilities from vesting restricted stock, multiple transactions coded “F” withheld a total of 11,332 common shares at $1.97 per share. Following these transactions, Buck directly beneficially owns 93,462 shares of common stock, which include 38,000 unvested restricted shares, as well as 13,000 stock options.
Lisata Therapeutics, Inc. director Steven M. Klosk received an equity award of 30,456 shares of common stock in the form of restricted stock units. The grant was made on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan at a price of $0 per share, reflecting a compensatory award rather than a purchase.
The 30,456 restricted stock units will vest on January 9, 2027. After this grant, Klosk beneficially owns a total of 95,815 shares of common stock, which includes the 30,456 unvested restricted stock units reported in this filing, all held as direct ownership.
Lisata Therapeutics director Heidi Henson reported a new equity award. On January 9, 2026 she received 30,456 shares of common stock in the form of restricted stock units granted under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
The restricted stock units are scheduled to vest on January 9, 2027, meaning the shares will become fully owned at that time if vesting conditions are met. After this grant, Henson beneficially owns 85,725 shares of Lisata common stock, which includes 30,456 unvested restricted stock units. The filing characterizes her ownership as direct.
Lisata Therapeutics director Cynthia Louise Flowers reported an equity grant from the company. On January 9, 2026, she was awarded 30,456 shares of common stock in the form of restricted stock units under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.
These 30,456 restricted stock units are scheduled to vest on January 9, 2027. After this grant, Flowers beneficially owns 95,446 shares of Lisata common stock, which includes the 30,456 unvested restricted stock units.
Lisata Therapeutics director Gregory B. Brown reported receiving 30,456 restricted stock units of common stock on January 9, 2026 under the company’s 2018 Equity Incentive Compensation Plan. These restricted stock units are scheduled to vest on January 9, 2027. Following this grant, he beneficially owns 95,659 shares of Lisata Therapeutics common stock, including 30,456 unvested restricted stock units.
Lisata Therapeutics director granted restricted stock units
Lisata Therapeutics, Inc. director Mohammad Azab reported an award of 30,456 shares of common stock on January 9, 2026. The filing states these are restricted stock units granted under the company’s 2018 Equity Incentive Compensation Plan and that they will vest on January 9, 2027. The units were recorded at a price of $0 per share, reflecting that this was an equity grant rather than an open-market purchase.
After this grant, Azab is reported to beneficially own 104,925 shares of common stock, which the disclosure notes includes 30,456 unvested restricted stock units. The ownership is reported as held directly.